Overall survival results from Ariel3: A phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma Meeting Abstract
| Authors: | Coleman, R. L.; Oza, A.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.; Clamp, A.; Scambia, G.; Leary, A.; Holloway, R.; Gancedo, M. A.; Fong, P.; Goh, J.; O'Malley, D.; Goble, S.; Maloney, L.; Ledermann, J. |
| Abstract Title: | Overall survival results from Ariel3: A phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma |
| Meeting Title: | IGCS 2022 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 32 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 Sep 29-Oct 1 |
| Meeting Location: | New York, NY |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2022-12-01 |
| Start Page: | A3 |
| End Page: | A4 |
| Language: | English |
| ACCESSION: | WOS:000899252300006 |
| DOI: | 10.1136/ijgc-2022-igcs.5 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: O003/#557 -- Source: Wos |
